代平颗粒对2型糖尿病大鼠糖、脂代谢及氧化应激的影响

为观察中药代平颗粒对2型糖尿病大鼠糖、脂代谢及氧化应激的影响,采用高脂饮食喂养联合STZ尾静脉注射方法建立2型糖尿病大鼠模型,将代平颗粒分为高、低两个剂量组给糖尿病大鼠灌胃,以二甲双胍为阳性药物对照进行实验.结果表明代平颗粒高剂量组能较好的降低STZ致糖尿病大鼠的血糖水平,调节血脂代谢,降低血清丙二醛(MDA)含量,升高超氧化物岐化酶(SOD)活性,修复胰岛损伤.代平颗粒能显著改善2型糖尿病大鼠糖-脂代谢,其机制可能与抑制体内氧化应激反应,修复链脲佐菌素所致的胰岛损伤有关.     

氧化应激与2型糖尿病

胰岛素抵抗、胰岛β细胞功能受损是2型糖尿病的主要病因。高血糖、高血脂导致在代谢过程中,线粒体产生大量活性氧,其可损坏线粒体功能,引起氧化应激反应。氧化应激可以激活细胞内的一系列应激信号通路,如JNK／SAPK、p38MAPK、IKKβ／NF-kβ和氨基己醣通路等。这些应激通路的激活可以产生以下结果：（1）阻断胰岛素作用通路,导致胰岛素抵抗;（2）降低胰岛素基因表达水平;（3）抑制胰岛素分泌;（4）促进β细胞凋亡等。本文主要针对活性氧的产生、氧化应激诱导胰岛素抵抗和胰岛β细胞功能受损等机制加以综述,以便进一步阐明2型糖尿病的发病机理。     

有氧运动和谷氨酰胺对二型糖尿病大鼠氧化应激及相关因子表达的影响

目的:探讨有氧运动和谷氨酰胺(Gln)对二型糖尿病(T2MD)大鼠抗氧化应激及炎性因子的影响。方法:用链脲佐菌素(STZ)诱导糖尿病大鼠模型,将成年雄性SD大鼠50只,6周龄,随机分为5组(n=10):包括安静对照组(N)、糖尿病对照组(D)、糖尿病施加有氧运动组(DE)、糖尿病施加谷氨酰胺组(DG)、糖尿病施加有氧运动+谷氨酰胺组(DEG)。6周后,检测干预后糖尿病大鼠糖脂代谢、抗氧化应激及炎性因子等相关指标,并探讨影响炎症反应的可能机制。结果:与N组相比,D组大鼠血清MDA、血糖、TC、TG、胰岛素、瘦素、TNF-α水平均明显升高(P<0.01),血清中SOD、GSH-Px、脂联素、HDL-C的水平均明显降低(P<0.01);与D组相比,三个干预组血清中MDA、血糖、TC、TG、胰岛素、瘦素、TNF-α水平降低,血清中HDL-C、SOD、GSH-Px、脂联素的水平均明显升高(P<0.05,P<0.01),且两者联合对上述指标的改善作用更为明显(P<0.01)。结论:有氧运动和Gln均能缓解糖尿病大鼠糖脂代谢及紊乱、氧化应激损伤及炎症反应,两者联合对其作用优于单一作用。     

氧化应激与2型糖尿病的研究进展

氧化应激与2型糖尿病(T2DM)的发生、发展密切相关.胰岛素抵搞(Insulin Resistance,IR)、胰岛β细胞功能受损是2型糖尿病的主要病因.而氧化应激可以直接及间接激活细胞内的一系列应激信号通路,如核因子κ-B(Nuclear factor-KappaB,NF-κB)、c-Jun氨基端激酶(NH-terminal Jun kinase,JNK)、蛋白激酶C(protein kinase C,PKC)、p38丝裂原活化蛋白激酶(Mitogen-activated protein kinase,MAPK)等.这些应激通路的激活可以产生以下结果:(1)阻断胰岛素作用通路,导致胰岛素抵抗;(2)降低胰岛素基因表达水平,致胰岛素合成和分泌减少;(3)促进胰岛β细胞凋亡等.本文针对氧化应激诱导胰岛素抵抗和胰岛β细胞功能受损等机制加以综述,以便进一步阐明2型糖尿病的发病机制.     

α-亚麻酸对糖尿病大鼠炎症介质和氧化应激的影响

目的:观察α-亚麻酸(ALA)对糖尿病大鼠体内炎症介质和氧化应激的影响,探讨ALA在糖尿病防治中的作用。方法:雄性SD大鼠高脂饮食喂养4周后,腹腔注射链脲佐菌素(STZ)30 mg/kg建立2型糖尿病(T2DM)模型。将大鼠随机分为3组(n=10):正常对照组、糖尿病模型组和ALA治疗组(500μg/kg.d)。4周后测定大鼠血清中肿瘤坏死因子(TNF-α)、可溶性P-选择素(sP-selectin)、可溶性细胞间黏附分子(sICAM-1)、一氧化氮(NO)、丙二醛(MDA)的含量以及超氧化物岐化酶(SOD)和过氧化氢酶(CAT)的活性。结果:与正常对照组相比,糖尿病大鼠血清中炎症介质TNF-α、sP-selectin和sICAM-1的含量增加,血清NO含量下降而MDA升高,同时抗氧化酶SOD和CAT的活性降低;ALA治疗可显著降低糖尿病大鼠血清中TNF-α、sP-selectin和sICAM-1的含量(与STZ+vehicle组相比,P<0.01),增加血清NO水平并减少MDA含量,升高抗氧化酶SOD和CAT的活性(与STZ+vehicle组相比,均P<0.05)。结论:ALA可显著降低糖尿病大鼠血清炎症介质的生成,减轻氧化应激水平,具有抗炎和抗氧化作用。提示ALA对糖尿病及糖尿病并发症的发生发展可能具有一定的防治作用。     

芪卫颗粒对2型糖尿病大鼠肾脏氧化应激和病理的影响

目的:研究芪卫颗粒对2型糖尿病大鼠肾脏氧化应激和病理的影响。方法:先诱导2型糖尿病大鼠模型50只,按照随机数字表法将大鼠分为A组和B组,每组25只,另选取25只正常鼠为对照组;A组给予芪卫颗粒,B组给予a-硫辛酸,均治疗3个月,检测3组血糖(BG)、糖化血红蛋白(Hb A1c)、血脂、肾功能指标、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽氧化物酶(GSH-Px),并观察肾脏的病理变化。结果:A组BG、Hb A1c和血脂水平均显著优于B组,差异有统计学意义(P0.05);A组肾功能指标与对照组比较无统计学意义(P0.05),A组肾功能指标显著优于B组,差异有统计学意义(P0.05);A组SOD、MDA和GSH-Px均优于B组,差异有统计学意义(P0.05);A组肾小球病理变化显著优于B组,差异有统计学意义(P0.05)。结论:芪卫颗粒对2型糖尿病大鼠肾脏氧化应激有一定抑制作用,能改善肾功能和病理。     

栀子水提取物对实验性2型糖尿病大鼠血糖及同型半胱氨酸水平的影响

观察栀子提取物对实验性2型糖尿病大鼠血糖、血脂及同型半胱氨酸水平的影响.采用Wistar雄性大鼠70只,随机抽取10只作为正常对照组,喂以普通维持饲料,其余60只高糖高脂饲料喂养4周后,ip链脲佐菌素(STZ)30 mg/kg建立2型糖尿病模型,7d后选取成模大鼠50只随机分为模型对照组(生理盐水)、盐酸二甲双胍对照组、栀子提取物低、中、高剂量组(0.2、0.4、0.6 g/kg),每组10只.连续ig给药4周后,观察各组大鼠血糖、血脂及同型半胱氨酸水平等变化.栀子提取物ig能降低糖尿病大鼠的血糖、甘油三酯(TG)、胆固醇(TC)、低密度脂蛋白(LDLC),同时能升高高密度脂蛋白(HDLC),降低同型半胱氨酸水平.     

普罗布考对糖尿病大鼠肾组织氧化应激的影响

目的研究普罗布考（Probucol）对糖尿病大鼠肾组织氧化应激的影响。方法采用腹腔注射链脲佐菌素（STZ）建立糖尿病大鼠模型。30只Wistar大鼠分为正常对照组（NC）、糖尿病组（DM）、糖尿病普罗布考治疗组（DP）。8周末称取体重、肾重、计算肾肥大指数（肾重/体重）,检测尿白蛋白排泄率（UAER）;测定各组生化指标包括血糖（BG）、胆固醇（TC）、三酰甘油（TG）、血清肌酐（SCr）、血尿素氮（BUN）;检测肾组织中丙二醛（MDA）的含量及超氧化物歧化酶（SOD）、过氧化氢酶（CAT）与谷胱甘肽过氧化物酶（GSH-Px）活性;肾组织切片行PAS染色分析肾小球面积及肾小球体积。结果 DM组大鼠肾重、肾重/体重、UAER、TC、TG、SCr、BUN、肾小球面积、肾小球体积较NC组均明显增加,DP组上述改变较DM组均明显减轻（P〈0.05）。DP组肾组织中MDA含量明显低于DM组,SOD、CAT、GSH-Px活性明显高于DM组（P〈0.05）。结论普罗布考可能部分通过减轻肾组织氧化应激反应实现对糖尿病大鼠肾脏的保护作用。     

玉米胚SOD提取物对糖尿病大鼠血糖、血脂及血清氧化应激状态的影响

目的:探讨玉米胚SOD提取物对于糖尿病大鼠血糖及主要脏器抗氧化能力的影响.方法:成年雄性Wistar大鼠36只,随机分为以下6组:1)正常对照组;2)糖尿病模型组:腹腔注射四氧嘧啶175mg/kg,连续两天;3)二甲基双胍对照组:糖尿病模型+灌服10mg/kg盐酸二甲基双胍;4)SOD高剂量组:糖尿病模型+灌服0.3gSOD提取物;5)SOD中剂量组:糖尿病模型+灌服0.18g SOD提取物;6)SOD低剂量组:糖尿病模型+灌服0.06g SOD提取物.连续3周,动态监测血糖,血清总胆固醇和甘油三酯.45天后处死动物,提取血清,采用硫代巴比妥酸法测定脂质过氧化产物丙二醛(MDA)含量;DTNB法测定还原型谷胱甘肽(GSH)含量;黄嘌呤氧化酶法测定超氧化物歧化酶(SOD)活力.结果:不同剂量的玉米胚SOD提取物对四氧嘧啶所致高血糖模型大鼠具有明显的降低血糖作用,可降低血清中总胆固醇和甘油三酯.并使血清MDA水平降低,抗氧化物质GSH含量增加,SOD活力升高.结论:玉米胚SOD提取物具有一定的降低血糖、血脂功效,可能与增加机体抗氧化能力有关.     

2型糖尿病合并急性脑梗死患者血糖波动对体内氧化应激及炎症因子水平的影响及意义

目的:探讨2型糖尿病(T2DM)合并急性脑梗死(ACI)患者血糖波动对体内氧化应激及炎症因子水平的影响及意义。方法:选取2014年3月到2017年1月第四军医大学唐都医院收治的T2DM合并ACI患者100纳入观察组,另选取同期在医院接受治疗的单纯T2DM患者82例作为对照组,比较两组患者的血糖水平标准差(SDBG)、日内平均血糖波动幅度(MAGE)、日间血糖波动幅度(MODD)、平均餐后血糖波动幅度(MPPGE)、丙二醛(MDA)、尿8-异前列腺素F_(2α)(8-iso-PGF_(2α))、肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP),并采用Spearman相关分析分析MAGE与MDA、8-iso-PGF_(2α)、hs-CRP、TNF-α的相关性。结果:观察组的SDBG、MAGE、MPPGE、MDA、8-iso-PGF_(2α)、hs-CRP、TNF-α均高于对照组,差异有统计学意义(P0.05),两组的MODD比较差异无统计学意义(P0.05)。经Spearman相关分析,MAGE与MDA、8-iso-PGF_(2α)、hs-CRP、TNF-α均呈正相关(r=0.657,0.732,0.724,0.538,P=0.013,0.009,0.010,0.021)。结论:与单纯T2DM患者相比,T2DM合并ACI患者存在较大的血糖波动,同时MAGE与患者体内的氧化应激及炎症因子水平呈正相关,临床上可通过控制血糖波动来降低患者的氧化应激反应程度及炎症因子水平,以改善患者的病情。     

葛脾煎剂对2型糖尿病大鼠血糖、血脂的影响

目的:探讨葛脾煎剂对实验性糖尿病大鼠血糖、血脂及胰岛素的影响.方法:利用链脲佐茵素建立2型糖尿病大鼠动物模型.将其随机分为糖尿病模型组(n=11)、葛脾煎剂组(n=11)及二甲双胍组(n=9),并设置正常对照组(n=10).治疗8周,观察治疗期间及治疗后大鼠的一般状况,检测大鼠血糖、总胆固醇(TC)、甘油三脂(TG)、血胰岛素,并计算胰岛素敏感指数(ISI).结果:葛脾煎荆可改善糖尿病大鼠基本状况,治疗组与糖尿病模型组比较,血糖、TC、TG、空腹胰岛素明显降低(P＜0.05),ISI明显提高.二甲双胍组血糖下降幅度、ISI提高幅度大于葛脾煎剂组(P＜0.05),胰岛素下降幅度及血脂改善程度两治疗组无明显差异(P＞0.05).结论:葛脾煎剂对糖尿病大鼠具有降糖、改善血脂、提高胰岛素敏感性的作用,其疗效与二甲双胍相似.     

Effects of beta-carotene on oxidative stress in normal and diabetic rats

Increasing interest in the role of oxidative stress and beta-carotene in disease and prevention led us to examine the results of beta-carotene's administration in diabetic rats, a model for high-oxidative stress. In this experiment, amounts of lipid peroxidation, glutathione, and glutathione disulfide, and activity levels of catalase, glutathione peroxidase, glutathione reductase, superoxide dismutase, and gamma-glutamyl transpeptidase were measured in the liver, kidney, and heart of Sprague-Dawley rats with streptozotocin-induced diabetes, and after treatment with 10 mg/kg/day of beta-carotene for 14 days. Beta-carotene treatment resulted in the reversal of the diabetes-induced increase in hepatic and cardiac catalase activity, the decreased levels of glutathione disulfide in the heart, and the increased cardiac and renal levels of lipid peroxidation. Treatment with beta-carotene exacerbated the increased glutathione peroxidase activity in the heart and the decreased catalase activity in the kidneys. In contrast to reduced hepatic glutathione levels in untreated diabetic rats, beta-carotene treatment increased glutathione levels in diabetic rats. Increased hepatic gamma-glutamyl transpeptidase activity in diabetic rats was not reduced by treatment. Thus, beta-carotene therapy for 14 days prevented/reversed some, but not all, diabetes-induced changes in oxidative stress parameters.     

Effects of pycnogenol treatment on oxidative stress in streptozotocin-induced diabetic rats

Free radicals and oxidative stress have been implicated in the etiology of diabetes and its complications. This in vivo study has examined whether subacute administration of pycnogenol, a French pine bark extract containing procyanidins that have strong antioxidant potential, alters biomarkers of oxidative stress in normal and diabetic rats. Diabetes was induced in female Sprague-Dawley rats by a single injection of streptozotocin (90 mg/kg body weight, ip), resulting (after 30 days) in subnormal body weight, increased serum glucose concentrations, and an increase in liver weight, liver/body weight ratios, total and glycated hemoglobin, and serum aspartate aminotransferase activity. Normal and diabetic rats were treated with pycnogenol (10 mg/kg body weight/day, ip) for 14 days. Pycnogenol treatment significantly reduced blood glucose concentrations in diabetic rats. Biochemical markers for oxidative stress were assessed in the liver, kidney, and heart. Elevated hepatic catalase activity in diabetic rats was restored to normal levels after pycnogenol treatment. Additionally, diabetic rats treated with pycnogenol had significantly elevated levels of reduced glutathione and glutathione redox enzyme activities. The results demonstrate that pycnogenol alters intracellular antioxidant defense mechanisms in streptozotocin-induced diabetic rats.     

Effects of leptin on oxidative stress in healthy and Streptozotocin-induced diabetic rats

Aims/hypothesis It is generally accepted that oxidative stress is responsible for etiology and complications of diabetes. During uncontrolled Type 1 diabetes, plasma leptin levels rapidly fall. However, it is not known whether diabetes-induced hypoleptinemia has any role in oxidative stress related to uncontrolled Type I diabetes. The present study was designed to examine the effects of leptin treatment on plasma lipid peroxidation and reduced glutathion of normal and streptozotocin(STZ)-induced diabetic rats. Methods Diabetes was induced by single injection of Streptozotocin (55 mg/kg bw). One week after induction of diabetes, rats began 5-day treatment protocol of leptin injections of (0.1 mg/kg bw i.p.) or same volume vehicle. At the end of the 5th day, rats were sacrificed by cardiac puncture under anesthesia and their plasma was taken for plasma leptin, malondialdehyde, and reduced glutathione measurements. Results Plasma leptin levels decreased in STZ-induced diabetic rats while plasma glucose, TBARS, and GSH levels increased. Plasma leptin levels were not affected with leptin treatment in both diabetic and non-diabetic rats. The elevation in plasma TBARS associated with STZ diabetes decreased with leptin treatment. Leptin also increased plasma GSH levels in diabetic rats. In non-diabetic rats, treatment with leptin did not change plasma TBARS and GSH levels. Conclusions/interpretations In conclusion, leptin treatment is able to attenuate lipid peroxidation in STZ-diabetic rats, in the onset of diabetes, by increasing the GSH levels without affecting hyperglycemia and hypoleptinemia.     

Effect of AOB, a fermented-grain food supplement, on oxidative stress in type 2 diabetic rats

Reactive oxygen species (ROS) play an important role in the pathogenesis of diabetic complications. Antioxidant Biofactor (AOB) is a mixture of commercially available fermented grain foods and has strong antioxidant activity. This study investigated the effect of AOB supplementation of standard rat food on markers of oxidative stress and inflammation in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes. Blood glucose, hemoglobin A1c, plasma free fatty acid, triacylglycerol and plasminogen activator inhibitor-1 (PAI-1) were significantly higher in OLETF rats than in non-diabetic control Long-Evans Tokushima Otsuka (LETO) rats at 29 weeks. AOB (6.5% of diet) was given to rats during 29-33 weeks of diabetic phase in OLETF rats. OLETF rats with AOB supplementation showed decreased blood glucose, hemoglobin A1c, triacyglycerol, low density lipoprotein, cholesterol and PAI-1. Mitochondrial ROS production was significantly increased in heart, aorta, liver and renal artery of OLETF rats. Uncoupling protein 2 (UCP2) is known to regulate ROS production. We found aortic UCP2 protein expression increased in OLETF rats, and AOB returned UCP2 expression to normal. Aortic endothelial NO synthase (eNOS) was also increased in OLETF rats more than in LETO rats at 33 weeks. In contrast, phosphorylated vasodilator-stimulated phosphoprotein, an index of the NO-cGMP pathway, was significantly diminished. AOB increased eNOS proteins in LETO and OLETF rats. In conclusion, AOB significantly improved the NO-cGMP pathway via normalizing ROS generation in OLETF rats. The data suggest that dietary supplementation with AOB contributes to nutritional strategies for the prevention and treatment of type 2 diabetes mellitus.     

Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats

Increased oxidative stress and impaired antioxidant defense mechanisms are important factors in the pathogenesis and progression of diabetes mellitus and other oxidant-related diseases. This study was designed to determine whether alpha-lipoic acid, which has been shown to have substantial antioxidant properties, when administered (10 mg/kg ip) once daily for 14 days to normal and diabetic female Sprague-Dawley rats would prevent diabetes-induced changes in biomarkers of oxidative stress in liver, kidney and heart. Serum glucose concentrations, aspartate aminotransferase activity, and glycated hemoglobin levels, which were increased in diabetes, were not significantly altered by alpha-lipoic acid treatment. Normal rats treated with a high dose of alpha-lipoic acid (50 mg/kg) survived but diabetic rats on similar treatment died during the course of the experiment. The activity of glutathione peroxidase was increased in livers of normal rats treated with alpha-lipoic acid, but decreased in diabetic rats after alpha-lipoic acid treatment. Hepatic catalase activity was decreased in both normal and diabetic rats after alpha-lipoic acid treatment. Concentrations of reduced glutathione and glutathione disulfide in liver were increased after alpha-lipoic acid treatment of normal rats, but were not altered in diabetics. In kidney, glutathione peroxidase activity was elevated in diabetic rats, and in both normal and diabetic animals after alpha-lipoic acid treatment. Superoxide dismutase activity in heart was decreased in diabetic rats but normalized after treatment with alpha-lipoic acid; other cardiac enzyme activities were not influenced by either diabetes or antioxidant treatment. These results suggest that after 14 days of treatment with an appropriate pharmacological dose, alpha-lipoic acid may reduce oxidative stress in STZ-induced diabetic rats, perhaps by modulating the thiol status of the cells.     

Effects of isoeugenol on oxidative stress pathways in normal and streptozotocin-induced diabetic rats.

Because some complications of diabetes mellitus may result from oxidative damage, we investigated the effects of subacute treatment (10mg/kg/day, intraperitoneal [ip], for 14 days) with the antioxidant isoeugenol on the oxidant defense system in normal and 30-day streptozotocin-induced diabetic Sprague-Dawley rats. Liver, kidney, brain, and heart were assayed for degree of lipid peroxidation, reduced and oxidized glutathione content, and activities of the free radical-detoxifying enzymes catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase. All tissues from diabetic animals exhibited disturbances in antioxidant defense when compared with normal controls. Treatment with isoeugenol reversed diabetic effects on hepatic glutathione peroxidase activity and on oxidized glutathione concentration in brain. Treatment with the lipophilic compound isoeugenol also decreased lipid peroxidation in both liver and heart of normal animals and decreased hepatic oxidized glutathione content in both normal and diabetic rats. Some effects of isoeugenol treatment, such as decreased activity of hepatic superoxide dismutase and glutathione reductase in diabetic rats, were unrelated to the oxidative effects of diabetes. In heart of diabetic animals, isoeugenol treatment resulted in an exacerbation of already elevated activities of catalase. These results indicate that isoeugenol therapy may not reverse diabetic oxidative stress in an overall sense.     

Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats

Oxidative stress is involved in the initiation and development of atherosclerosis in diabetes. We tested the hypothesis that oxidative stress is already increased in early stage type II diabetes, and that troglitazone may prevent the increase. Three groups of 20 week old rats were studied: untreated Otsuka Long-Evans Tokushima Fatty (OLETF) rats, as an animal model of type II diabetes, OLETF rats treated with troglitazone, and control Long-Evans Tokushima Otsuka (LETO) rats. Plasma lipid hydroperoxides (LOOH) concentration, as an indication of lipid peroxidation, and superoxide dismutase (SOD) activity in the thoracic aorta were measured. Plasma LOOH concentration was significantly higher in non-treated OLETF rats compared to LETO rats and treatment with troglitazone completely prevented this increase. SOD activity was significantly decreased in non-treated OLETF rats compared to LETO rats and troglitazone attenuated the diminution of it. These observations demonstrate oxidative stress is already increased in the early stage of type II diabetes and we confirmed troglitazone has the effect of an antioxidant in vivo.